Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2013

View Archived Issues

Celon Pharma characterizes novel FGFR inhibitor

Pharmacological and behavioral characterization of a murine model of chronic migraine

Bioinformatics screening identifies antidepressant drugs that have anticancer potential

LEO Pharma commits to increasing transparency of clinical trial data

Atheris and Debiopharm Group to collaborate on lead optimization for oncolytic venom peptide

Evotec achieves first milestones in immunology collaboration with UCB

Preclinical and first clinical data presented for GS-5737

Prevenar 13 launched in Japan

Cells of a patient with Unverricht-Lundborg disease corrected for splice defect

Rigel provides update on two pipeline candidates

FDA advisory committee votes in favor of sofosbuvir for chronic HCV

Kyowa Hakko Kirin updates activities of third quarter 2013

Boehringer Ingelheim Pharma discloses new HCMV DNA polymerase inhibitors

AstraZeneca synthesizes novel beta-lactamase inhibitors for bacterial infections

Columbia University prepares new ferroptosis modulators

LabCorp launches FDA-approved companion diagnostic for colorectal cancer

Amgen divulges novel PI3Kdelta inhibitors

Amorfix Life Sciences detects misfolded SOD1 in sporadic ALS

Actelion receives positive CHMP opinion for Opsumit in PAH

Synflorix receives positive opinion from the EMA's CHMP for additional indication

Novel SYK inhibitor HM-0523 proves effective as antiarthritic drug in preclinical models

Mologen files application in Belgium to conduct trial in small cell lung cancer

Cimzia gets positive opinion for PsA and approval for severe active axial spondyloarthritis

FDA extends approval of Lundbeck's Sabril

Vaccine targeting IDO safe and well tolerated in first-in-human study

Pulmatrix reports completion of first part of phase Ib study of PUR-0200 in COPD

Milestone Pharmaceuticals begins phase I trial of MSP-2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....